Evidence map›Paper›PMID 27285161›Full record

ArticleJournal of magnetic resonance imaging : JMRI2016

Patient-specific pharmacokinetic parameter estimation on dynamic contrast-enhanced MRI of prostate: Preliminary evaluation of a novel AIF-free estimation method.

Shoshana B Ginsburg, Pekka Taimen, Harri Merisaari, Paula Vainio, Peter J Boström, Hannu J Aronen, Ivan Jambor, Anant Madabhushi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of magnetic resonance imaging : JMRI, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shoshana B GinsburgDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-5764-8524
Pekka TaimenDepartment of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Harri MerisaariDepartment of Diagnostic Radiology, University of Turku, Turku, Finland.
Paula VainioDepartment of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Peter J BoströmDepartment of Urology, Turku University Hospital, Turku, Finland.
Hannu J AronenDepartment of Diagnostic Radiology, University of Turku, Turku, Finland.
Ivan JamborDepartment of Diagnostic Radiology, University of Turku, Turku, Finland.
Anant MadabhushiDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.

Funding

Software to facilitate multimode, multiscale fused data for Pathology and RadioloR01CA136535 · NCI · UNIVERSITY OF PENNSYLVANIA · PI FELDMAN, MICHAEL D, MADABHUSHI, ANANT · 2009 to 2013
$3.2M
Computerized histologic image predictor of cancer outcomeR01CA202752 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FELDMAN, MICHAEL D, GANESAN, SHRIDAR · 2016 to 2020
$3.1M
Prostate-cancer Imaging by Combined Ultrasound and Magnetic-resonance ParametersR01CA140772 · NCI · RIVERSIDE RESEARCH INSTITUTE · PI FELEPPA, ERNEST JOSEPH · 2010 to 2014
$3.0M
Pathology Image Informatics Platform for visualization, analysis and managementU24CA199374 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GURCAN, METIN NAFI, MADABHUSHI, ANANT · 2015 to 2019
$2.9M
Comprehensive quantitative ultrafast 3D liver MRIR01DK098503 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI GULANI, VIKAS, SEIBERLICH, NICOLE · 2013 to 2017
$2.6M
Decision support with MRI for targeting, evaluating laser ablation for prostate cR21CA167811 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI MADABHUSHI, ANANT · 2012 to 2013
$516k
Histologic image-based aggressiveness prediction in p16+ oropharyngeal carcinomaR21CA179327 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MADABHUSHI, ANANT · 2014 to 2015
$389k
Computerized morphologic-molecular predictor of progression in DCISR21CA195152 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI BADVE, SUNIL S., MADABHUSHI, ANANT · 2015 to 2016
$388k
Decision Support System for Predicting outcome of ER+ breast cancersR43EB015199 · NIBIB · IBRIS, INC. · PI GANESAN, SHRIDAR, HARDING, DAVE · 2011 to 2011
$207k
NCI NIH HHS R01 CA136535NCI NIH HHS R01 CA202752NCI NIH HHS R21 CA167811NCI NIH HHS R21 CA179327NCI NIH HHS R21 CA195152NCI NIH HHS U24 CA199374NIBIB NIH HHS R43 EB015199NIDDK NIH HHS R01 DK098503
6 · The paper itself

Abstract

purposeTo develop and evaluate a prostate-based method (PBM) for estimating pharmacokinetic parameters on dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) by leveraging inherent differences in pharmacokinetic characteristics between the peripheral zone (PZ) and transition zone (TZ). MATERIALS AND

methodsThis retrospective study, approved by the Institutional Review Board, included 40 patients who underwent a multiparametric 3T MRI examination and subsequent radical prostatectomy. A two-step PBM for estimating pharmacokinetic parameters exploited the inherent differences in pharmacokinetic characteristics associated with the TZ and PZ. First, the reference region model was implemented to estimate ratios of K

resultsSignificant differences (P < 0.05) in PBM K

conclusionPharmacokinetic parameters estimated via PBM outperformed AIF-based parameters in PCa detection. J. Magn. Reson. Imaging 2016;44:1405-1414.

Indexed as

Models, BiologicalAdultAlgorithmsComputer SimulationContrast MediaDiagnosis, DifferentialHumansImage EnhancementImage Interpretation, Computer-AssistedMagnetic Resonance ImagingMaleMeglumineMetabolic Clearance RateMiddle AgedOrganometallic CompoundsPilot ProjectsContrast Mediagadoterate meglumineMeglumineOrganometallic CompoundsDCE MRIpharmacokinetic modelingprostate cancer

Identifiers

PMID27285161
PMCPMC5559229

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.